Clinical Trials: Solanezumab in Alzheimer's Disease
From Bloomberg:
Eli Lilly Shares Rise on Alzheimer’s Drug Hopes
By Drew Armstrong and Robert Langreth
Dec 6, 2011
[snip]
"Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s disease. Pfizer Inc. (PFE), Johnson & Johnson and Elan are testing bapineuzumab, a similar drug."
[snip]
Read the article
Eli Lilly Shares Rise on Alzheimer’s Drug Hopes
By Drew Armstrong and Robert Langreth
Dec 6, 2011
[snip]
"Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s disease. Pfizer Inc. (PFE), Johnson & Johnson and Elan are testing bapineuzumab, a similar drug."
[snip]
Read the article
Labels: Alzheimer, clinical trials, dementia, lilly, neurodegenerative, neuropsychology, pharmaceuticals
posted by Anthony Risser at 1:48 PM
0 Comments:
Post a Comment
<< Home